1
|
Sweeney MT, Gunnett L, Kumar DM, Lunt BL, Moulin V, Barrett M, Gurjar A, Doré E, Pedraza JR, Bade D, Machin C. Antimicrobial susceptibility of mastitis pathogens isolated from North American dairy cattle, 2011-2022. Vet Microbiol 2024; 291:110015. [PMID: 38340554 DOI: 10.1016/j.vetmic.2024.110015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 01/24/2024] [Accepted: 02/01/2024] [Indexed: 02/12/2024]
Abstract
A total of 10,890 bacterial isolates of Streptococcus dysgalactiae, Streptococcus uberis, Staphylococcus aureus and Escherichia coli isolated as etiological agents from dairy cows with mastitis by 29 veterinary laboratories across North America between 2011 and 2022 were tested for in vitro antimicrobial susceptibility by broth microdilution to ampicillin, cefoperazone, ceftiofur, cephalothin, erythromycin, oxacillin, penicillin-novobiocin and pirlimycin according to CLSI standards. Using available clinical breakpoints, antimicrobial resistance among S. dysgalactiae (n = 2406) was low for penicillin-novobiocin (0% resistance), ceftiofur (0.1%), erythromycin (3.2%) and pirlimycin (4.6%). Among S. uberis (n = 2398), resistance was low for ampicillin (0%) and ceftiofur (0.2%) and moderate for erythromycin (11.9%) and pirlimycin (18.4%). For S. aureus (n = 3194), resistance was low for penicillin-novobiocin (0%), ceftiofur (0.1%), oxacillin (0.2%), erythromycin (0.7%), cefoperazone (1.2%) and pirlimycin (2.8%). For E. coli (n = 2892), resistance was low for ceftiofur (2.8%) and cefoperazone (3.4%) and moderate for ampicillin (9.2%). Overall, the results indicate that mastitis pathogens in the United States and Canada have not shown any substantial changes in the in vitro susceptibility to antimicrobial drugs over the 12 years of the study, or among that of the proceeding survey from 2002-2010. The data support the conclusion that resistance to common antimicrobial drugs among mastitis pathogens, even to drugs that have been used in dairies for mastitis management for many years, continues to remain low.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Don Bade
- Microbial Research, Inc., Fort Collins, CO, USA
| | | |
Collapse
|
2
|
Varnier R, Toullec C, Philonenko S, Dupré A, Artru P, Hafliger E, Drouillard A, Torregrosa C, Pernot S, McLellan P, Lecomte T, Moulin V, Lécaille C, Touchefeu Y, Locher C, Taieb J, Coutzac C. Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study. Dig Liver Dis 2024:S1590-8658(24)00270-6. [PMID: 38403514 DOI: 10.1016/j.dld.2024.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Revised: 02/03/2024] [Accepted: 02/11/2024] [Indexed: 02/27/2024]
Abstract
BACKGROUND Prior trials validated triplet chemotherapy (Tri-CT) with bevacizumab as first line treatment for metastatic colorectal cancer (mCRC) but real-world data are scarce and practices remain heterogeneous. AIMS To evaluate Tri-CT +/- bevacizumab efficacy and safety, and to identify factors influencing treatment decisions. METHODS The COLOTRIP retrospective study enrolled mCRC patients treated from 2014 to 2019 in 14 French centers. RESULTS Of 299 patients (81% PS 0-1, 58% RAS-mutated and 19% BRAF-mutated), 51% received Tri-CT and 49% Tri-CT + bevacizumab. Metastatic disease was classified as resectable (6.5%), potentially resectable (40%), and unresectable (54%). Bevacizumab use was associated with primary tumor location, mutational status and number of metastases. Median overall survival was 33.5 months in the Tri-CT group and 23.9 months in the Tri-CT + bevacizumab group, with median progression-free survival being 14.5 and 11.4 months. After adjusting for initial characteristics, no difference in survival was noted. Around 30% of patients experienced grade ≥3 adverse events. CONCLUSIONS This study highlights several factors influencing Tri-CT use +/- bevacizumab decision and confirms the real-world good oncological outcomes and tolerability of these regimens in mCRC patients. Our results suggest that Tri-CT alone may by an appropriate option for specific subgroups of patients.
Collapse
Affiliation(s)
- R Varnier
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Research on Healthcare Performance (RESHAPE, Inserm U1290), Université Claude Bernard Lyon 1, Lyon, France
| | - C Toullec
- Department of Digestive Oncology, Institut du Cancer Avignon-Provence, Avignon, France
| | - S Philonenko
- Department of Gastroenterology and Digestive Oncology, Hôpital Pitié Salpêtrière, Paris, France
| | - A Dupré
- Department of Surgery, Centre Léon Bérard, Lyon, France
| | - P Artru
- Department of Gastroenterology and Digestive Oncology, Hôpital Privé Jean Mermoz, Lyon, France
| | - E Hafliger
- Department of Gastroenterology and Digestive Oncology, Hôpital Privé Jean Mermoz, Lyon, France
| | - A Drouillard
- Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Dijon, Dijon, France
| | - C Torregrosa
- Department of Medical Oncology, Institut Curie, Paris, France
| | - S Pernot
- Department of Digestive Oncology, Institut Bergonié, Bordeaux, France
| | - P McLellan
- Department of Hepato-Gastroenterology and Digestive Oncology, Hôpital Saint-Louis, Paris, France
| | - T Lecomte
- Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Tours, Tours, France
| | - V Moulin
- Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier de La Rochelle, La Rochelle, France
| | - C Lécaille
- Department of Hepato-Gastroenterology and Digestive Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
| | - Y Touchefeu
- Department of Hepato-Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - C Locher
- Department of Hepato-Gastroenterology, Centre Hospitalier de Meaux, Meaux, France
| | - J Taieb
- Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, AP-HP, Paris-Cité University, SIRIC CARPEM Comprehensive Cancer Center, Paris, France
| | - C Coutzac
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Association des Gastro-Entérologues Oncologues (AGEO), France.
| |
Collapse
|
3
|
Sánchez-Castro MA, Vukasinovic N, Passafaro TL, Salmon SA, Asper DJ, Moulin V, Nkrumah JD. Effects of a mastitis J5 bacterin vaccination on the productive performance of dairy cows: An observational study using propensity score matching techniques. J Dairy Sci 2023; 106:7177-7190. [PMID: 37210353 DOI: 10.3168/jds.2022-23166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Accepted: 04/18/2023] [Indexed: 05/22/2023]
Abstract
Inferring causal effects between variables when utilizing observational data is challenging due to confounding factors not controlled through a randomized experiment. Propensity score matching can decrease confounding in observational studies and offers insights about potential causal effects of prophylactic management interventions such as vaccinations. The objective of this study was to determine potential causality and impact of vaccination with an Escherichia coli J5 bacterin on the productive performance of dairy cows applying propensity score matching techniques to farm-recorded (e.g., observational) data. Traits of interest included 305-d milk yield (MY305), 305-d fat yield (FY305), 305-d protein yield (PY305), and somatic cell score (SCS). Records from 6,418 lactations generated by 5,121 animals were available for the analysis. Vaccination status of each animal was obtained from producer-recorded information. Confounding variables considered were herd-year-season groups (56 levels), parity (5 levels: 1, 2, 3, 4, and ≥5), and genetic quartile groups (4 levels: top 25% through bottom 25%) derived from genetic predictions for MY305, FY305, PY305, and SCS, as well as for the genetic susceptibility to mastitis. A logistic regression model was applied to estimate the propensity score (PS) for each cow. Subsequently, PS values were used to form pairs of animals (1 vaccinated with 1 unvaccinated control), depending on their PS similarities (difference in PS values of cows within a match required to be <20% of 1 standard deviation of the logit of PS). After the matching process, 2,091 pairs of animals (4,182 records) remained available to infer the causal effects of vaccinating dairy cows with the E. coli J5 bacterin. Causal effects estimation was performed using 2 approaches: simple matching and a bias-corrected matching. According to the PS methodology, causal effects of vaccinating dairy cows with a J5 bacterin on their productive performance were identified for MY305. The simple matched estimator suggested that vaccinated cows produced 163.89 kg more milk over an entire lactation when compared with nonvaccinated counterparts, whereas the bias-corrected estimator suggested that such increment in milk production was of 150.48 kg. Conversely, no causal effects of immunizing dairy cows with a J5 bacterin were identified for FY305, PY305, or SCS. In conclusion, the utilization of PS matching techniques applied to farm-recorded data was feasible and allowed us to identify that vaccination with an E. coli J5 bacterin relates to an overall milk production increment without compromising milk quality.
Collapse
|
4
|
Jolivet S, Couturier J, Grohs P, Vilfaillot A, Zahar JR, Frange P, Casetta A, Moulin V, Lawrence C, Baune P, Bourgeois C, Bouffier A, Laussucq C, Sienzonit L, Picard S, Podglajen I, Kassis-Chikhani N, Barbut F. Prevalence and risk factors of toxigenic Clostridioides difficile asymptomatic carriage in 11 French hospitals. Front Med (Lausanne) 2023; 10:1221363. [PMID: 37547619 PMCID: PMC10402895 DOI: 10.3389/fmed.2023.1221363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 06/28/2023] [Indexed: 08/08/2023] Open
Abstract
Clostridioides difficile infection (CDI) incidence has increased over the last 20 years. Studies suggest that asymptomatic carriers may be an important reservoir of C. difficile in healthcare settings. We conducted a point prevalence study to estimate the toxigenic C. difficile asymptomatic carriage rate and the associated risk factors in patients >3 years old. Between September 16, 2019 and January 15, 2020, all patients hospitalized in 11 healthcare facilities in the Paris urban area were included in the study. They were screened on the day of the survey for toxigenic C. difficile carriage by rectal swab and interviewed. Isolates were characterized by PCR ribotyping and multiplex PCR targeting toxin genes. A logistic regression model was used to determine the risk factors associated with toxigenic C. difficile asymptomatic carriage using uni- and multivariate analysis in the subpopulation of patients >3 years old. During the study period, 2,389 patients were included and screened. The median age was 62 years (interquartile range 35-78 years) and 1,153 were male (48.3%). Nineteen patients had a previous CDI (0.9%). Overall, 185/2389 patients were positive for C. difficile (7.7%), including 93 toxigenic strains (3.9%): 77 (82.8%) were asymptomatic (prevalence 3.2%) whereas 12 (12.9%) were diarrheic. Prevalences of toxigenic C. difficile were 3.5% in patients >3 years old and 7.0% in ≤3 years old subjects, respectively. Toxigenic strains mainly belonged to PCR ribotypes 106 (n = 14, 15.0%), 014 (n = 12, 12.9%), and 020 (n = 10, 10.8%). Among toxigenic strains, 6 (6.4%) produced the binary toxin. In multivariate analysis, two factors were positively associated with toxigenic C. difficile asymptomatic carriage in patients >3 years old: multidrug-resistant organisms co-carriage [adjusted Odd Ratio (aOR) 2.3, CI 95% 1.2-4.7, p = 0.02] and previous CDI (aOR 5.8, CI 95% 1.2-28.6, p = 0.03). Conversely, consumption of raw milk products were associated with reduced risk of toxigenic C. difficile colonization (aOR 0.5, CI 95% 0.2-0.9, p = 0.01). We showed that there was a low prevalence of asymptomatic toxigenic C. difficile carriage in hospitalized patients. Consumption of raw milk prevents toxigenic C. difficile colonization, probably due to the barrier effect of milk-associated bacteria.
Collapse
Affiliation(s)
- Sarah Jolivet
- Unité de prévention du risque infectieux, Hôpital Saint Antoine, Paris, France
| | - Jeanne Couturier
- Laboratoire de microbiologie de l’environnement, Hôpital Saint Antoine, Paris, France
- National Reference Laboratory for Clostridioides difficile, Paris, France
| | - Patrick Grohs
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Aurélie Vilfaillot
- Unité de Recherche Clinique, Hôpital Européen Georges Pompidou, Paris, France
- INSERM Centre d’Investigation Clinique 1418, Paris, France
| | - Jean-Ralph Zahar
- Unité de Prévention du Risque infectieux, Hôpitaux Avicenne, Bobigny/Jean Verdier, Bondy/René Muret, Sevran, France
| | - Pierre Frange
- Équipe de Prévention du Risque infectieux, Laboratoire de microbiologie clinique, Hôpital Necker – Enfants malades, Groupe hospitalier Assistance Publique – Hôpitaux de Paris (APHP) Centre – Université Paris Cité, Paris, France
| | - Anne Casetta
- Équipe de Prévention du Risque infectieux, Hôpital Cochin, Paris, France
| | - Véronique Moulin
- Équipe de Prévention du Risque infectieux, Hôpitaux Corentin Celton/Vaugirard, Issy-les-Moulineaux, France
| | - Christine Lawrence
- Équipe de Prévention du Risque infectieux, GHU Paris-Saclay site R. Poincaré, Garches, France
| | - Patricia Baune
- Équipe de Prévention du Risque infectieux, Hôpital Paul Brousse, Villejuif, France
| | - Cléo Bourgeois
- Unité de Recherche Clinique, Hôpital Européen Georges Pompidou, Paris, France
- INSERM Centre d’Investigation Clinique 1418, Paris, France
| | - Axel Bouffier
- Unité de Recherche Clinique, Hôpital Européen Georges Pompidou, Paris, France
- INSERM Centre d’Investigation Clinique 1418, Paris, France
| | - Claudine Laussucq
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Lydia Sienzonit
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Simon Picard
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Isabelle Podglajen
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Najiby Kassis-Chikhani
- Équipe de Prévention du Risque infectieux, Hôpital Européen Georges Pompidou, Paris, France
| | - Frédéric Barbut
- Unité de prévention du risque infectieux, Hôpital Saint Antoine, Paris, France
- Laboratoire de microbiologie de l’environnement, Hôpital Saint Antoine, Paris, France
- National Reference Laboratory for Clostridioides difficile, Paris, France
| |
Collapse
|
5
|
Grohs P, Vilfaillot A, Zahar JR, Barbut F, Frange P, Casetta A, Moulin V, Lawrence C, Baune P, Bourgeois C, Bouffier A, Laussucq C, Sienzonit L, Picard S, Podglajen I, Kassis-Chikhani N. Faecal carriage of multidrug-resistant bacteria and associated risk factors: results from a point prevalence study. J Antimicrob Chemother 2022; 77:2667-2678. [PMID: 36031727 DOI: 10.1093/jac/dkac289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 08/01/2022] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES Since 2003, incidences of carbapenemase-producing Gram-negative bacilli (CP-GNB) and vancomycin-resistant Enterococcus faecium (VRE) have steadily increased in France. We therefore conducted a point prevalence study to estimate carriage rates of CP-GNB, VRE and ESBL-producing Enterobacterales (ESBL-PE) and associated risk factors. METHODS Between September 2019 and January 2020, all inpatients hospitalized on a given day in 11 teaching hospitals in the Paris urban area were eligible. Patient interviews and rectal swab screening results were recorded by dedicated nurses. The swabs were plated onto selective chromogenic media and processed using the GeneXpert® system. RESULTS Of 2396 patients, 364 (15.2%) yielded at least one multiresistant bacterial isolate, including 29 CP-GNB carriers (1.2%), 13 VRE carriers (0.5%) and 338 ESBL-PE carriers (14%). In 15 patients (4.4% of ESBL-PE carriers and 36.6% of CP-GNB/VRE carriers), concomitant CP-GNB/VRE and ESBL-PE carriage was observed. In 7/29 CP-GNB and 7/13 VRE carriers, carbapenemase production and vanA in the screening samples was only detected with Xpert® tests. The OXA-48 gene was predominant in 13/34 CP-GNB isolates from 29 carriers. From the 338 ESBL-PE carriers, 372 isolates were recovered, mainly Escherichia coli (61.2%). Among 379 children, 1.1% carried a CP-GNB/VRE strain, and 12.4% carried an ESBL strain. Previous hospitalization outside mainland France, previous antimicrobial treatment and previous ESBL-PE carriage were the main risk factors associated with CP-GNB and/or VRE carriage. CONCLUSIONS The low CP-GNB and VRE prevalence likely reflects the French policy to limit intrahospital spread of CP-GNB and VRE strains.
Collapse
Affiliation(s)
- Patrick Grohs
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Aurélie Vilfaillot
- Unité de Recherche Clinique, Hôpital Européen Georges Pompidou, Paris, France.,INSERM Centre d'Investigation Clinique 1418 (CIC1418), Paris, France
| | - Jean Ralph Zahar
- Equipe Opérationnelle en Hygiène, Hôpitaux Avicenne, Bobigny/Jean Verdier, Bondy/René Muret, Sevran, France
| | - Frédéric Barbut
- Equipe Opérationnelle en Hygiène, Hôpital St Antoine, Paris, France
| | - Pierre Frange
- Equipe Opérationnelle en Hygiène, Laboratoire de microbiologie clinique, Hôpital Necker - Enfants malades, Paris, France
| | - Anne Casetta
- Equipe Opérationnelle en Hygiène, Hôpital Cochin, Paris, France
| | - Véronique Moulin
- Equipe Opérationnelle en Hygiène, Hôpitaux Corentin Celton/Vaugirard, Issy-les-Moulineaux, France
| | - Christine Lawrence
- Equipe Opérationnelle en Hygiène, GHU Paris-Saclay site R, Poincaré, APHP, Garches, France
| | - Patricia Baune
- Equipe Opérationnelle en Hygiène, Hôpital Paul Brousse, Villejuif, France
| | - Cléo Bourgeois
- Unité de Recherche Clinique, Hôpital Européen Georges Pompidou, Paris, France.,INSERM Centre d'Investigation Clinique 1418 (CIC1418), Paris, France
| | - Axel Bouffier
- Unité de Recherche Clinique, Hôpital Européen Georges Pompidou, Paris, France.,INSERM Centre d'Investigation Clinique 1418 (CIC1418), Paris, France
| | - Claudine Laussucq
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Lydia Sienzonit
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Simon Picard
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Isabelle Podglajen
- Laboratoire de microbiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - Najiby Kassis-Chikhani
- Equipe Opérationnelle en Hygiène, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
6
|
Attiogbe E, Larochelle S, Mainzer C, Closs B, Gilbert C, Moulin V. 761 Contribution of resident immune cells in a human autologous 3D skin model. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
7
|
Monel B, Planas D, Grzelak L, Smith N, Robillard N, Staropoli I, Goncalves P, Porrot F, Guivel-Benhassine F, Guinet ND, Rodary J, Puech J, Euzen V, Bélec L, Orvoen G, Nunes L, Moulin V, Fourgeaud J, Wack M, Imbeaud S, Campagne P, Duffy D, Santo JPD, Bruel T, Péré H, Veyer D, Schwartz O. Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study. EBioMedicine 2021; 73:103637. [PMID: 34678613 PMCID: PMC8526063 DOI: 10.1016/j.ebiom.2021.103637] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 10/06/2021] [Accepted: 10/06/2021] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND The dynamics of SARS-CoV-2 alpha variant shedding and immune responses at the nasal mucosa remain poorly characterised. METHODS We measured infectious viral release, antibodies and cytokines in 426 PCR+ nasopharyngeal swabs from individuals harboring non-alpha or alpha variants. FINDINGS With both lineages, viral titers were variable, ranging from 0 to >106 infectious units. Rapid antigenic diagnostic tests were positive in 94% of samples with infectious virus. 68 % of individuals carried infectious virus within two days after onset of symptoms. This proportion decreased overtime. Viable virus was detected up to 14 days. Samples containing anti-spike IgG or IgA did not generally harbor infectious virus. Ct values were slightly but not significantly lower with alpha. This variant was characterized by a fast decrease of infectivity overtime and a marked release of 13 cytokines (including IFN-b, IP-10 and IL-10). INTERPRETATION The alpha variant displays modified viral decay and cytokine profiles at the nasopharyngeal mucosae during symptomatic infection. FUNDING This retrospective study has been funded by Institut Pasteur, ANRS, Vaccine Research Institute, Labex IBEID, ANR/FRM and IDISCOVR, Fondation pour la Recherche Médicale.
Collapse
Affiliation(s)
- Blandine Monel
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France
| | - Delphine Planas
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Creteil, France
| | - Ludivine Grzelak
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France; Université de Paris, Sorbonne Paris Cité, Paris, France
| | - Nikaïa Smith
- Translational Immunology Lab, Department of Immunology, Inserm U1223, Institut Pasteur, Paris
| | - Nicolas Robillard
- Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de Microbiologie, Paris, France
| | - Isabelle Staropoli
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France
| | - Pedro Goncalves
- Innate Immunity Unit, Department of Immunology, Department of Immunology, Inserm U1223, Institut Pasteur, Paris; Inserm U1223, Paris, France
| | - Françoise Porrot
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France
| | - Florence Guivel-Benhassine
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France
| | | | - Julien Rodary
- Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de Microbiologie, Paris, France
| | - Julien Puech
- Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de Microbiologie, Paris, France
| | - Victor Euzen
- Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de Microbiologie, Paris, France
| | - Laurent Bélec
- Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de Microbiologie, Paris, France; Hôpital européen Georges Pompidou INSERM U970, PARCC, Faculté de Médecine, Université de Paris, Paris, France
| | - Galdric Orvoen
- Hôpital Vaugirard, Service de gériatrie, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Léa Nunes
- Hôpital Corentin Celton, Service de gériatrie, Assistance Publique-Hôpitaux de Paris, Issy-les-Moulineaux, France
| | - Véronique Moulin
- Hôpital Corentin Celton, Service de gériatrie, Assistance Publique-Hôpitaux de Paris, Issy-les-Moulineaux, France
| | - Jacques Fourgeaud
- Université de Paris, EHU 7328 PACT, Institut Imagine, Paris, France; Virology Department, AP-HP, Necker Enfants Malades Hospital, Paris, France
| | - Maxime Wack
- Hôpital Européen Georges Pompidou, Département d'Informatique Médicale, Biostatistiques et Santé Publique
| | - Sandrine Imbeaud
- INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France
| | | | - Darragh Duffy
- Translational Immunology Lab, Department of Immunology, Inserm U1223, Institut Pasteur, Paris
| | - James P Di Santo
- Innate Immunity Unit, Department of Immunology, Department of Immunology, Inserm U1223, Institut Pasteur, Paris; Inserm U1223, Paris, France
| | - Timothée Bruel
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Creteil, France
| | - Hélène Péré
- INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France
| | - David Veyer
- Hôpital Européen Georges Pompidou, Laboratoire de Virologie, Service de Microbiologie, Paris, France; INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France
| | - Olivier Schwartz
- Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France; CNRS UMR 3569, Paris, France; Vaccine Research Institute, Creteil, France.
| |
Collapse
|
8
|
Varnier R, Toullec C, Fonnesu M, Philonenko S, Artru P, Hafliger E, Drouillard A, Torregrosa C, Pernot S, McLellan P, Lecomte T, Moulin V, Lecaille C, Touchefeu Y, Locher C, Turpin A, Taieb J, Coutzac C. 421P FOLFIRINOX with or without targeted therapy as first line for metastatic colorectal cancer: An AGEO multicenter real-world study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Chaib Y, Larochelle S, Mainzer C, Closs B, Gilbert C, Moulin V. 591 A New 3D Skin Model Containing Autologous Immune Cells Reconstructed by Tissue Engineering. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Vaillancourt-Audet M, Rochette P, Blais M, Moulin V, Auger F. 775 Development of a model to study the influence of ultraviolet radiation (UVs) on cell migration of primary melanoma. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
11
|
Chaib Y, Larochelle S, Mainzer C, Closs B, Gilbert C, Moulin V. 902 A new 3D immunocompetent skin model reconstructed by tissue engineering. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Moulin V, Alameda L, Baumann PS, Gholamrezaee MM, Palix J, Gasser J, Conus P. [Three clinical risk profiles of violent behavior in a cohort of early psychosis patients]. Encephale 2018; 45:214-220. [PMID: 30446287 DOI: 10.1016/j.encep.2018.08.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 08/21/2018] [Accepted: 08/26/2018] [Indexed: 10/27/2022]
Abstract
OBJECTIVE This study aims to determine whether it is possible to identify clinical profiles at risk of violent behaviors (VB) in the early phase of psychotic disorders, on the basis of the main dynamic psychopathological risk factors and describe characteristics of the groups with highest levels of violent behaviors. METHOD A total of 265 patients, aged 18 to 35, treated at the Treatment and early Intervention in Psychosis Program (TIPP-Lausanne), a specialized early psychosis program, were included in this study. We conducted a latent-class analysis and a discriminative analysis on the basis of the main dynamic VB risk factors: substance use disorder, impulsivity, positive symptoms, insight, aggression, hostility, anger, emotional instability and adherence to treatment. These factors were evaluated by specialized scales and on the basis of the Positive and Negative Syndrome Scale (PANSS). VB were restricted to physical aggression against people, defined as "serious violence". They were assessed on the basis of a questionnaire listing violent offenses (Swiss Criminal Code) and VB such as assault and battery, information through the forensic psychiatric services and on the basis of the Staff Observation Aggression Scale (SOAS-R scale) during inpatient treatment phase. RESULTS Four heterogeneous subgroups were identified with respect to the studied clinical characteristics, including two groups with high rates of VB. The first group, comprising 46% of patients with VB, is distinguished by the prevalence of a range of dimensions related to hostility, impulsivity and emotional instability, associated with high levels of substance abuse and positive symptoms. These clinical dimensions are very significant at the statistical level, since they explain 70% of the construction of subgroups (discriminant analysis). The second group with 37% of patients with VB, is characterized by a lack of insight, lack of adherence to treatment and substance use. These two clinical profiles could increase the impairment of cognitive, functional and relational abilities and contribute to the development of VB in this early phase of psychosis. The third subgroup, with a violent behaviors rate of 28.6%, is distinguished by its high proportion of diagnoses of substance abuse (100%) and women (54%). A last subgroup of patients, the largest quantitatively, has a low proportion of VB (15%) and the lowest levels on the studied factors, suggesting that the majority of patients with this profile commit few VB. CONCLUSION Our results show that it is possible to identify groups at risk of violent behaviors during the early phase of psychosis on the basis of clinical characteristics that may evolve and therefore be the focus of preventive care. These results highlight the need to target substance use, impulsivity and lack of insight at follow-up in order to prevent VB.
Collapse
Affiliation(s)
- V Moulin
- Unité de recherche en psychiatrie et psychologie légales, institut de psychiatrie légale, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), site de Cery, bâtiment Les Cèdres, 1008 Prilly-Lausanne, Suisse.
| | - L Alameda
- Service de psychiatrie générale, centre de neuroscience psychiatrique, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), Lausanne, Suisse; Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - P S Baumann
- Service de psychiatrie générale, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), Lausanne, Suisse
| | - M M Gholamrezaee
- Centre d'épidémiologie psychiatrique et psychopathologie, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), Lausanne, Suisse
| | - J Palix
- Unité de recherche en psychiatrie et psychologie légales, institut de psychiatrie légale, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), site de Cery, bâtiment Les Cèdres, 1008 Prilly-Lausanne, Suisse
| | - J Gasser
- Institut de psychiatrie légale, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), Lausanne, Suisse
| | - P Conus
- Service de psychiatrie générale, département de psychiatrie du centre hospitalier universitaire Vaudois (CHUV), Lausanne, Suisse
| |
Collapse
|
13
|
Tougeron D, Cohen R, Sueur B, Sefrioui D, Gentilhomme L, Lecomte T, Aparicio T, Des Guetz G, Artru P, de la Fouchardiere C, Moulin V, Hautefeuille V, Coriat R, Touchefeu Y, Lecaille C, Goujon G, Ferru A, Taieb J, André T, Zaanan A. A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.059] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Vargas A, Peltier A, Dubé J, Lefebvre-Lavoie J, Moulin V, Goulet F, Lavoie JP. Evaluation of contractile phenotype in airway smooth muscle cells isolated from endobronchial biopsy and tissue specimens from horses. Am J Vet Res 2017; 78:359-370. [DOI: 10.2460/ajvr.78.3.359] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
15
|
Makoschey B, van Kilsdonk E, Hubers WR, Vrijenhoek MP, Smit M, Wichgers Schreur PJ, Kortekaas J, Moulin V. Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. PLoS Negl Trop Dis 2016; 10:e0004550. [PMID: 27031621 PMCID: PMC4816553 DOI: 10.1371/journal.pntd.0004550] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 02/24/2016] [Indexed: 11/18/2022] Open
Abstract
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that affects domesticated ruminants and occasionally humans. Classical RVF vaccines are based on formalin-inactivated virus or the live-attenuated Smithburn strain. The inactivated vaccine is highly safe but requires multiple administrations and yearly re-vaccinations. Although the Smithburn vaccine provides solid protection after a single vaccination, this vaccine is not safe for pregnant animals. An alternative live-attenuated vaccine, named Clone 13, carries a large natural deletion in the NSs gene which encodes the major virulence factor of the virus. The Clone 13 vaccine was previously shown to be safe for young lambs and calves. Moreover, a study in pregnant ewes suggested that the vaccine could also be applied safely during gestation. To anticipate on a possible future incursion of RVFV in Europe, we have evaluated the safety of Clone 13 for young lambs and pregnant ewes. In line with the guidelines from the World Organisation for Animal health (Office International des Epizooties, OIE) and regulations of the European Pharmacopeia (EP), these studies were performed with an overdose. Our studies with lambs showed that Clone 13 dissemination within vaccinated animals is very limited. Moreover, the Clone 13 vaccine virus was not shed nor spread to in-contact sentinels and did not revert to virulence upon animal-to-animal passage. Importantly, a large experiment with pregnant ewes demonstrated that the Clone 13 virus is able to spread to the fetus, resulting in malformations and stillbirths. Altogether, our results suggest that Clone 13 can be applied safely in lambs, but that caution should be taken when Clone 13 is used in pregnant animals, particularly during the first trimester of gestation.
Collapse
Affiliation(s)
- Birgit Makoschey
- Intervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands
- * E-mail:
| | - Emma van Kilsdonk
- Intervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands
| | - Willem R. Hubers
- Intervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands
| | - Mieke P. Vrijenhoek
- Intervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands
| | - Marianne Smit
- Intervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands
| | - Paul J. Wichgers Schreur
- Department of Virology, Central Veterinary Institute, Wageningen University and Research Centre, Lelystad, The Netherlands
| | - Jeroen Kortekaas
- Department of Virology, Central Veterinary Institute, Wageningen University and Research Centre, Lelystad, The Netherlands
| | - Véronique Moulin
- Intervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands
| |
Collapse
|
16
|
Moulin V, Abbiati M, Azzola A, Palix J, Gasser J. [Risk assessment in forensic psychiatric reports: what kind assessment instrument? What indicator? What practical?]. Rev Med Suisse 2015; 11:1710-1714. [PMID: 26591082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Here we present results of studies conducted by the Research Unit of Legal Psychiatry and Psychology of Lausanne about risk assessment and protective factors in the evaluation of violence recidivism. It aims to help experts in considering the relevance and use of tools at their disposal. Particular attention is given to the significance of protective factors and impulsive dimensions, as to the inter-raters process that leads to the final deliberations.
Collapse
|
17
|
Batxelli-Molina I, Calvayrac-Pawlowski S, Moulin V, Lapalus M, Hem S, Laune D, Asselah T, Jardin-Watelet B. Novel α-2-macroglobulin cleaved fragments as biomarkers of early liver fibrosis in patients with chronic hepatitis C. Future Virol 2015. [DOI: 10.2217/fvl.14.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
ABSTRACT Aim: Liver biopsy is considered the gold standard for the diagnosis and staging of hepatic fibrosis in patients with chronic hepatitis C and is now progressively replaced by noninvasive procedures. We aimed at improving α-2-macroglobulin diagnostic value for liver fibrosis by identifying new isoforms that may be specifically related to early stages of the pathology. Materials & methods: α-2-Macroglobulin isoforms were characterized in serum samples from patients with chronic hepatitis C and mild (F1) to moderate (F2) fibrosis by proteomic methods. Results: New biological 40 kDa C-terminal α-2-macroglobulin fragments were identified as potential biomarkers of early fibrosis (fold change = 1.55; p < 0.01). Conclusion: The serum concentration of α-2-macroglobulin fragments allows a better differentiation of F1 and F2 fibrosis stages than total α-2-macroglobulin isoforms.
Collapse
Affiliation(s)
- Isabelle Batxelli-Molina
- SysDiag – UMR 3145 CNRS/Bio-Rad, Complex System Modeling and Engineering for Diagnosis, Cedex, France
| | | | - Véronique Moulin
- SysDiag – UMR 3145 CNRS/Bio-Rad, Complex System Modeling and Engineering for Diagnosis, Cedex, France
| | - Martine Lapalus
- Service d’Hépatologie and INSERM U773, CRB3, Université Paris Diderot, Hôpital Beaujon, Clichy, France
| | - Sonia Hem
- INRA UR1199, Laboratoire de Protéomique Fonctionnelle, Montpellier, France
| | - Daniel Laune
- SysDiag – UMR 3145 CNRS/Bio-Rad, Complex System Modeling and Engineering for Diagnosis, Cedex, France
| | - Tarik Asselah
- Service d’Hépatologie and INSERM U773, CRB3, Université Paris Diderot, Hôpital Beaujon, Clichy, France
| | - Bénédicte Jardin-Watelet
- SysDiag – UMR 3145 CNRS/Bio-Rad, Complex System Modeling and Engineering for Diagnosis, Cedex, France
| |
Collapse
|
18
|
Kortekaas J, Oreshkova N, van Keulen L, Kant J, Bosch B, Bouloy M, Moulin V, Goovaerts D, Moormann R. Comparative efficacy of two next-generation Rift Valley fever vaccines. Vaccine 2014; 32:4901-8. [DOI: 10.1016/j.vaccine.2014.07.037] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 06/11/2014] [Accepted: 07/09/2014] [Indexed: 12/17/2022]
|
19
|
van der Sluijs MTW, Schroer-Joosten DPH, Fid-Fourkour A, Vrijenhoek MP, Debyser I, Moulin V, Moormann RJM, de Smit AJ. Transplacental transmission of Bluetongue virus serotype 1 and serotype 8 in sheep: virological and pathological findings. PLoS One 2013; 8:e81429. [PMID: 24358112 PMCID: PMC3864790 DOI: 10.1371/journal.pone.0081429] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Accepted: 10/13/2013] [Indexed: 11/24/2022] Open
Abstract
The Bluetongue virus serotype 8 (BTV-8) strain, which emerged in Europe in 2006, had an unusually high ability to cause foetal infection in pregnant ruminants. Other serotypes of BTV had already been present in Europe for more than a decade, but transplacental transmission of these strains had never been demonstrated. To determine whether transplacental transmission is a unique feature of BTV-8 we compared the incidence and pathological consequences of transplacental transmission of BTV-8 to that of BTV-1. Nine pregnant ewes were infected with either BTV-8 or BTV-1. The BTV strains used for the infection were field strains isolated on embryonated chicken eggs and passaged twice on mammalian cells. Blood samples were taken to monitor the viraemia in the ewes. Four weeks after the infection, the foetuses were examined for pathological changes and for the presence of BTV. BTV-8 could be demonstrated in 12 foetuses (43%) from 5 ewes (56%). %). BTV-1 was detected in 14 foetuses (82%) from 6 ewes (67%). Pathological changes were mainly found in the central nervous system. In the BTV-8 group, lympho-histiocytic infiltrates, gliosis and slight vacuolation of the neuropil were found. BTV-1infection induced a severe necrotizing encephalopathy and severe meningitis, with macroscopic hydranencephaly or porencephaly in 8 foetuses. In our experimental setting, using low passaged virus strains, BTV-1 was able to induce transplacental transmission to a higher incidence compared to BTV-8, causing more severe pathology.
Collapse
Affiliation(s)
| | | | | | - Mieke P Vrijenhoek
- Animal Services and Pathology, MSD Animal Health, Boxmeer, The Netherlands
| | - Isolde Debyser
- CoVeToP, Consultancy in Veterinary and Toxicological Pathology, Enghien, Belgium
| | - Véronique Moulin
- Research and Development, MSD Animal Health, Boxmeer, The Netherlands
| | - Rob J M Moormann
- Central Veterinary Institute, Animal Sciences Group, Wageningen University and Research centre, Lelystad, The Netherlands ; Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Abraham J de Smit
- Research and Development, MSD Animal Health, Boxmeer, The Netherlands
| |
Collapse
|
20
|
Fourest B, Perrone J, Baglan N, Lindecker C, Moulin V. Surface Properties of Two Thorium Phosphate Compounds: Th4(P04)4P207 and Th3(P04)4; Comparison and Consequences for the Retention of Actinides. RADIOCHIM ACTA 2013. [DOI: 10.1524/ract.1998.82.special-issue.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- B. Fourest
- Institut de Physique Nucleaire, F-91406 Orsay cedex, France
| | - J. Perrone
- Institut de Physique Nucleaire, F-91406 Orsay cedex, France
| | - N. Baglan
- Institut de Protection et de sürete Nucleaire, DPHD/SDOS, F-92265 Fontenay-aux-Roses cedex, France
| | - C. Lindecker
- Institut de Physique Nucleaire, F-91406 Orsay cedex, France
| | - V. Moulin
- CEA/DCC/DESD/SESD, F-91191 Gif-sur-Yvette cedex, France
| |
Collapse
|
21
|
Garcia K, Boust D, Moulin V, Douville E, Fourest B, Guillaumont R. Multiparametric Investigation of the Reactions of Plutonium under Estuarine Conditions. RADIOCHIM ACTA 2013. [DOI: 10.1524/ract.1996.74.special-issue.165] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- K. Garcia
- Laboratoire de Radioécologie Marine IPSN BP 10, 50130 Octeville, France
| | - D. Boust
- Laboratoire de Radioécologie Marine IPSN BP 10, 50130 Octeville, France
| | - V. Moulin
- CEA, DCC/DESD/SESD/Section de Geochimie, 92265 Fontenay-aux-Roses, France
| | - E. Douville
- Laboratoire de Radioécologie Marine IPSN BP 10, 50130 Octeville, France
| | - B. Fourest
- Groupe de Radiochimie, Institut de Physique Nucléaire, Université Paris XI, 91406 Orsay Cedex, France
| | - R. Guillaumont
- Groupe de Radiochimie, Institut de Physique Nucléaire, Université Paris XI, 91406 Orsay Cedex, France
| |
Collapse
|
22
|
van der Sluijs MTW, Schroer-Joosten DPH, Fid-Fourkour A, Smit M, Vrijenhoek MP, Moulin V, de Smit AJ, Moormann RJM. Transplacental transmission of BTV-8 in sheep: BTV viraemia, antibody responses and vaccine efficacy in lambs infected in utero. Vaccine 2013; 31:3726-31. [PMID: 23746457 DOI: 10.1016/j.vaccine.2013.05.087] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2013] [Revised: 05/13/2013] [Accepted: 05/21/2013] [Indexed: 10/26/2022]
Abstract
Bluetongue virus (BTV) is an insect vector transmitted virus which causes an economically important disease in ruminants. BTV infection during pregnancy can result in infection of the foetus, which may lead to the birth of persistently infected or immunotolerant offspring. Since persistently infected animals continuously produce large amounts of virus they could be a source of infection for the insect vector. This could significantly influence the epidemiology of the virus and hence might require additional measures to control a BTV outbreak. Therefore, we investigated the potential of BTV-8 to induce persistent infection or immunotolerance in lambs in an experimental setting. Infection of eighteen 70-75 days pregnant ewes with wild type BTV-8 led to the birth of 25 out of 44 BTV RNA positive lambs (foetal infected, FI). All 23 FI lambs born alive also had anti BTV antibodies at birth; infectious virus could be recovered from 5 out of 25 FI lambs. Viral RNA loads decreased rapidly after birth; 19 out of 20 FI lambs that remained in the experiment until week 14 after birth, were RNA negative at that time. Since persistence of BTV-8 infection could not be demonstrated, we investigated whether foetal infection had an effect on protection against a field virus infection and on efficacy of vaccination. To this end, 5 FI lambs and 5 foetal non-infected (FNI) lambs were vaccinated with the inactivated Bovilis(®) BTV-8 vaccine, five months after birth. Three weeks after the vaccination, all lambs were infected with wild type BTV-8. The foetal infection did not interfere with vaccination efficacy. In contrast, foetal BTV-8 infection induced an immune response which afforded protection against BTV challenge comparable to the level of protection induced by vaccination.
Collapse
Affiliation(s)
- M T W van der Sluijs
- MSD Animal Health, Wim de Korverstraat 35, PO Box 31, 5830 AA Boxmeer, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Rioux LE, Moulin V, Beaulieu M, Turgeon SL. Human skin fibroblast response is differentially regulated by galactofucan and low molecular weight galactofucan. ACTA ACUST UNITED AC 2013. [DOI: 10.1016/j.bcdf.2013.03.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Moulin V, Gasser J. [Benefits and limitations of risk assessment for criminal recidivism]. Rev Med Suisse 2012; 8:1775-1780. [PMID: 23097915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The legislatives evolutions imply an important recourse to the psychiatric expertise in order to evaluate the potential dangerousness of a subject. However, in spite of the development of techniques and tools for this evaluation, the dangerousness assessment of a subject is in practice extremely complex and discussed in the scientific literature. The evolution of the concept of dangerousness to the risk assessment involved a technicisation of this evaluation which should not make forget the limits of these tools and the need for restoring the subject, the meaning and the clinic in this evaluation.
Collapse
Affiliation(s)
- V Moulin
- Unité de recherche en psychiatrie et psychologie Iégales, Département de psychiatrie, Site de Cery, 1008 Prilly-Lausanne.
| | | |
Collapse
|
25
|
Gubbins S, Hartemink NA, Wilson AJ, Moulin V, Vonk Noordegraaf CA, van der Sluijs MTW, de Smit AJ, Sumner T, Klinkenberg D. Scaling from challenge experiments to the field: Quantifying the impact of vaccination on the transmission of bluetongue virus serotype 8. Prev Vet Med 2012; 105:297-308. [PMID: 22425328 DOI: 10.1016/j.prevetmed.2012.02.016] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Revised: 01/25/2012] [Accepted: 02/19/2012] [Indexed: 11/18/2022]
Abstract
Bluetongue (BT) is an economically important disease of ruminants caused by bluetongue virus (BTV) and transmitted by Culicoides biting midges. The most practical and effective way to protect susceptible animals against BTV is by vaccination. Data from challenge studies in calves and sheep conducted by Intervet International b.v., in particular, presence of viral RNA in the blood of challenged animals, were used to estimate vaccine efficacy. The results of the challenge studies for calves indicated that vaccination is likely to reduce the basic reproduction number (R(0)) for BTV in cattle to below one (i.e. prevent major outbreaks within a holding) and that this reduction is robust to uncertainty in the model parameters. Sensitivity analysis showed that the whether or not vaccination is predicted to reduce R(0) to below one depended on the following assumptions: (i) whether "doubtful" results from the challenge studies are treated as negative or positive; (ii) whether or not the probability of transmission from host to vector is reduced by vaccination; and (iii) whether the extrinsic incubation period follows a realistic gamma distribution or the more commonly used exponential distribution. For sheep, all but one of the vaccinated animals were protected and, consequently, vaccination will consistently reduce R(0) in sheep to below one. Using a stochastic spatial model for the spread of BTV in Great Britain (GB), vaccination was predicted to reduce both the incidence of disease and spatial spread in simulated BTV outbreaks in GB, in both reactive vaccination strategies and when an incursion occurred into a previously vaccinated population.
Collapse
Affiliation(s)
- S Gubbins
- Institute for Animal Health, Pirbright Laboratory, Ash Road, Pirbright, Surrey GU24 0NF, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Moulin V, Noordegraaf CV, Makoschey B, van der Sluijs M, Veronesi E, Darpel K, Mertens PP, de Smit H. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine. Vaccine 2012; 30:2228-35. [DOI: 10.1016/j.vaccine.2011.11.100] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2011] [Revised: 11/22/2011] [Accepted: 11/25/2011] [Indexed: 10/14/2022]
|
27
|
Moulin V, Morgan ME, Eleveld-Trancikova D, Haanen JBAG, Wielders E, Looman MWG, Janssen RAJ, Figdor CG, Jansen BJH, Adema GJ. Targeting dendritic cells with antigen via dendritic cell-associated promoters. Cancer Gene Ther 2012; 19:303-11. [PMID: 22361816 DOI: 10.1038/cgt.2012.2] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The induction of tumor-specific immune responses is largely dependent on the ability of dendritic cells (DCs) to present tumor-associated antigens to T lymphocytes. Therefore, we investigated the use of DC-associated promoter-driven genetic vaccines to specifically target DC in vivo. Restricted expression of vaccine-encoding genes in DC should enhance specificity and improves their safety for clinical applications. Hereto, 3-5 kb upstream sequences of the murine genes encoding CD11c, DC-SIGN, DC-STAMP and Langerin were isolated, characterized and subcloned into enhanced green fluorescent protein (EGFP) reporter constructs. Upon electroporation, EGFP was expressed in DC cell lines, but not in other cell lines, confirming DC-restricted promoter activity. When these promoters were cloned into a construct upstream of the gene for ovalbumin (OVA), it appeared that DC-STAMP promoter-driven expression of OVA (pDCSTAMP/OVA) in DC yielded the most efficient OVA-specific CD4+ and CD8+ T-cell responses in vitro. Administration of pDC-STAMP/OVA in vivo, using the tattoo gun vaccination system, evoked specific immune responses as evidenced in a mouse tumor model. Adoptively transferred pDC-STAMP/OVA-transfected DCs induced strong CD8+ T-cell proliferation in vivo. These experiments demonstrate that our DC-directed promoter constructs are potential tools to restrict antigen expression in DC and could be implemented to modulate DC function by the introduction of relevant proteins.
Collapse
Affiliation(s)
- V Moulin
- Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Moulin V, Dellon P, Laurent O, Aubry S, Lubrano J, Delabrousse E. Toxic megacolon in patients with severe acute colitis: computed tomographic features. Clin Imaging 2012; 35:431-6. [PMID: 22040786 DOI: 10.1016/j.clinimag.2011.01.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2010] [Accepted: 01/06/2011] [Indexed: 10/15/2022]
Abstract
OBJECTIVE The objective of the study was to evaluate computed tomography (CT) in the differential diagnosis of patients with toxic megacolon (TM) complicating severe acute colitis (SAC) and patients with SAC but no TM. MATERIALS AND METHODS We identified 16 patients who presented clinically complicated SAC and CT examination before surgery. The CT scans of these patients were retrospectively evaluated in consensus by two abdominal radiologists blinded to the clinical and pathological results for CT findings of SAC, i.e., diffuse colonic wall thickening, submucosal edema, pericolonic fat stranding and ascites, and CT findings of TM reported in the literature, i.e., segmental colonic wall thinning, air-filled colonic distension over 6 cm with abnormal haustral pattern, nodular pseudopolyps and associated small bowel distension. Fisher's Exact Test was used for all statistical analyses. RESULTS Segmental colonic wall thinning with abnormal haustral pattern was noted in TM only (P=.001). As compared to patients with SAC but no TM as a complication, patients with TM showed statistically more frequent air-filled colonic distension over 6 cm (P=.001) and nodular pseudopolyps (P=.001). Diffuse colonic wall thickening (P=.036) and submucosal edema (P=.036) were more present in cases of uncomplicated SAC. Pericolonic fat stranding (P=.12), ascites (P=.6), and small bowel and gastric distension (P=1) were not distinctive criteria. CONCLUSION Computed tomography is useful in distinguishing patients with TM from patients with SAC but no TM as a complication. The association of air-filled colonic distension >6 cm, abnormal haustral pattern and segmental colonic parietal thinning seems pathognomonic of TM and should lead to rapid surgery.
Collapse
Affiliation(s)
- Véronique Moulin
- Department of Radiology, Besançon University Hospital, 3 bvd Flelming, F-25030 Besançon, France
| | | | | | | | | | | |
Collapse
|
29
|
Moulin V, Sévin AS, Senon JL. Conflictualisation psychique des positions professionnelles des surveillants en établissement pénitentiaire. PRAT PSYCHOL 2011. [DOI: 10.1016/j.prps.2009.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
van der Sluijs MTW, Schroer-Joosten DPH, Fid-Fourkour A, Vrijenhoek MP, Debyser I, Gregg DA, Dufe DM, Moulin V, Moormann RJM, de Smit AJ. Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers. Vaccine 2011; 30:647-55. [PMID: 22107846 DOI: 10.1016/j.vaccine.2011.10.106] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 10/17/2011] [Accepted: 10/30/2011] [Indexed: 11/16/2022]
Abstract
The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative. Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well. Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses.
Collapse
Affiliation(s)
- M T W van der Sluijs
- MSD Animal Health, Wim de Korverstraat 35, PO Box 31, 5830 AA, Boxmeer, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Labonne N, Moulin V, Stammose D. Actinide Sorption onto Silica in the Presence of Humic Substances: Proposal of Retentionmechanisms. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-257-307] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTThe experimental investigation and modelling of radionuclides sorption processes is an essential part of safety analyses of an underground repository of radioactive wastes in geological formations. Physico—chemical phenomena at oxide/solution interfaces have been studied in the case of the system constituted by amorphous silica and americium (III) in the presence of humic substances as organic complexing agents. The retention behaviour of Am(III) onto silica appears dependent on pH, ionic strength and in particular humic concentration. At a ionic strength of 0.1 M, the presence of low concentration of humic acids (1 mg/l) enhances the Am(III) retention in the pH range 3-5.5, whereas at higher pH, its uptake is largely decreased. At lower ionic strength (0.001 M), Am(III) retention on silica is highly lowered, in the pH range 3-7 in the presence of humic acids. Reversibility experiments show the desorption of americium in the absence of humic substances, and also the desorption of the humics on the silica with respect of the pH. The surface complexation model has been applied to our results in the different systems and apparent surface complexation constants have been determined.
Collapse
|
32
|
Bréard E, Belbis G, Hamers C, Moulin V, Lilin T, Moreau F, Millemann Y, Montange C, Sailleau C, Durand B, Desprat A, Viarouge C, Hoffmann B, de Smit H, Goutebroze S, Hudelet P, Zientara S. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats. Vaccine 2011; 29:2495-502. [PMID: 21256877 DOI: 10.1016/j.vaccine.2010.12.105] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2010] [Revised: 12/14/2010] [Accepted: 12/16/2010] [Indexed: 11/17/2022]
Abstract
Bluetongue serotype 8 has become a major animal health issue in the European Union and the European member States have agreed on a vaccination strategy, which involves only inactivated vaccines. In this study, the efficacy of two inactivated vaccines against bluetongue virus serotype 8 (BTV-8) used in Europe since 2008, BTVPUR ALSAP(®) 8 (MERIAL) and BOVILIS(®) BTV8 (Intervet/SP-AH), was evaluated in goats immunized and challenged with BTV-8 field isolates under experimental conditions. Serological, virological and clinical examinations were conducted before and after challenge. Three groups of 10 goats each (groups A, B and C) were randomly constituted and 2 groups (A and C) were subcutaneously vaccinated twice with one dose of the two commercial vaccines BTVPUR ALSAP 8 (group A) or BOVILIS BTV8 (group C) respectively. Animals of the groups A, C and B (B: controls) were challenged with a virulent inoculum containing BTV-8. During the experiment, it was found out that the BTV-8 challenge inoculum was contaminated with another BTV serotype. However, results demonstrated that vaccination of goats with two injections of BTVPUR ALSAP 8 or BOVILIS BTV8 provided a significant clinical protection against a BTV-8 challenge and completely prevented BTV-8 viraemia in all vaccinated animals. Qualitative data showed no difference in the kinetics and levels of the humoral response induced by these two inactivated vaccines.
Collapse
Affiliation(s)
- E Bréard
- ANSES, UMR Virology 1161, Laboratoire de Sante Animale, Maisons-Alfort, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
van der Sluijs M, Timmermans M, Moulin V, Noordegraaf CV, Vrijenhoek M, Debyser I, de Smit AJ, Moormann R. Transplacental transmission of Bluetongue virus serotype 8 in ewes in early and mid gestation. Vet Microbiol 2010; 149:113-25. [PMID: 21145670 DOI: 10.1016/j.vetmic.2010.11.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2010] [Revised: 10/29/2010] [Accepted: 11/01/2010] [Indexed: 11/16/2022]
Abstract
The ability of Bluetongue virus serotype 8 (BTV-8) originating from the 2006 European outbreak to cross the ovine placenta during early and mid gestation was investigated in two separate experiments. In the first experiment, 16 ewes were infected with BTV-8 at 70-75 days gestation. The foetuses were collected at 18-19 days after infection (dpi). BTV-8 could be isolated from at least two organs of 19 out of 40 lambs and from 11 out of 16 infected ewes. In the second experiment, 20 BTV-8 infected ewes in early gestation (day 40-45) were euthanized at 10 days (10 ewes) or 30 days (10 ewes) after infection. The presence of BTV could be demonstrated in two foetuses from two ewes at 10 dpi and in 4 foetuses from four ewes at 30 dpi. The main pathological findings in the foetuses in mid gestation were meningo-encephalitis and vacuolation of the cerebrum. In the foetuses early at gestation, haemorrhages in various foetal tissues and necrosis and haemorrhages in the placentomes were found. These experiments demonstrate for the first time the presence of infectious BTV in lamb foetuses at different stages of gestation, combined with a difference in transmission rate depending on the gestation stage. The high transmission rate found at mid term gestation (69%) makes our model very suitable for further research into the mechanisms of transplacental transmission and for research into the reduction of this route of transmission through vaccination.
Collapse
Affiliation(s)
- M van der Sluijs
- Intervet Schering Plough Animal Health, Wim de Körverstraat 35, PO Box 31, 5830 AA Boxmeer, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taïeb J, Bonnetain F, Aparicio T. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010; 21:1786-1793. [PMID: 20223786 DOI: 10.1093/annonc/mdq038] [Citation(s) in RCA: 101] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Small-bowel adenocarcinoma (SBA) is a rare tumor of poor prognosis. Data on the efficacy of chemotherapy for advanced SBA are scarce. PATIENTS AND METHODS All patients with advanced SBA who received frontline chemotherapy from 1996 to 2008 were eligible for this retrospective multicenter study. RESULTS Ninety-three consecutive patients were included. In the entire population, the median progression-free survival (PFS) and overall survival (OS) times were 6.6 and 15.1 months, respectively. Median PFS times among patients treated with LV5FU2 (n = 10), FOLFOX (n = 48), FOLFIRI (n = 19) and LV5FU2-cisplatin (n = 16) were 7.7, 6.9, 6.0 and 4.8 months, respectively, while median OS times were 13.5, 17.8, 10.6 and 9.3 months, respectively. In multivariate analysis, World Health Organization performance status (PS) (P < 0.0001) and elevated serum levels of carcinoembryonic antigen (CEA) (P = 0.02) and carbohydrate antigen 19-9 (CA 19-9) (P = 0.03) were the only variables significantly associated with poor OS. In the subgroup of patients treated with platinum-based chemotherapy, multivariate analysis showed that LV5FU2-cisplatin was associated with poorer PFS (P < 0.0001) and OS (P = 0.02) compared with FOLFOX. CONCLUSIONS This is the largest study of chemotherapy in advanced SBA. Baseline PS and CEA and CA 19-9 levels were the main prognostic factors. FOLFOX seems to be the most effective platinum-based chemotherapy regimen.
Collapse
Affiliation(s)
- A Zaanan
- Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique Hôpitaux de Paris, University Paris VI
| | - L Costes
- Department of Medicine, Institut Gustave Roussy, University Paris Sud, Villejuif
| | - M Gauthier
- Biostatistics and Epidemiological Unit, Georges François Leclerc Center, Dijon
| | - D Malka
- Department of Medicine, Institut Gustave Roussy, University Paris Sud, Villejuif
| | - C Locher
- Department of Hepato-Gastroenterology, Meaux Hospital, Meaux
| | - E Mitry
- Department of Hepatogastroenterology and Digestive Oncology, Ambroise Paré Hospital, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt
| | - D Tougeron
- Department of Hepatogastroenterology, Charles Nicolle Hospital, Rouen
| | - T Lecomte
- Department of Hepatogastroenterology, Trousseau Hospital, University François Rabelais, Tours
| | - J-M Gornet
- Department of Hepatogastroenterology, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris
| | - I Sobhani
- Department of Hepatogastroenterology, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, Créteil
| | - V Moulin
- Department of Medical Oncology, Louis Pasteur Hospital, Coudray
| | - P Afchain
- Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique Hôpitaux de Paris, University Paris VI
| | - J Taïeb
- Department of Hepatogastroenterology, Européen Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Paris
| | - F Bonnetain
- Biostatistics and Epidemiological Unit, Georges François Leclerc Center, Dijon
| | - T Aparicio
- Department of Gastroenterology, Avicenne Hospital, Assistance Publique Hôpitaux de Paris, University Paris XIII, Bobigny, France and AGEO (Association des Gastroente'rologues Oncologues/Gastroenterologists Oncologists Association).
| |
Collapse
|
35
|
Affiliation(s)
| | | | - V. Moulin
- CEA-DCC-DESD, BP6, 92265 Fontenay-aux-Roses Cedex, France
| | - J.-C. Petit
- CEA-DCC-DESD, BP6, 92265 Fontenay-aux-Roses Cedex, France
| | - V. Rigato
- INFM-Laboratori Nazionali 35020 Legnaro, Italy
| |
Collapse
|
36
|
Zaanan A, Costes L, Liegard M, Locher C, Bidault A, Mitry E, Gornet J, Tourgeron D, Mansourbakht T, Taieb J, Lecomte T, Moulin V, Maire F, Sobhani I, Afchain P, Malka D, Bonnetain F, Aparicio T. CO.32 Chimiothérapie des adénocarcinomes avancés de l’intestin grêle : résultats finaux de l’étude multicentrique AGEO. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/s0399-8320(09)72627-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Kuijk H, Jansen M, Moulin V, Makoschey B. [Vaccination against bluetongue serotype 8 in the Netherlands]. Tijdschr Diergeneeskd 2008; 133:1006-1009. [PMID: 19133439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
38
|
Mayrand D, Larochelle S, Lopez-Valle C, Roy M, Moulin V. 120
Interaction Between Endothelial Cells and Myofibroblasts During Wound Healing. Wound Repair Regen 2008. [DOI: 10.1111/j.1067-1927.2005.130216x.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Bellemare J, Bergeron D, Roberge C, Lopez-Valle C, Roy M, Moulin V. 150
Influence of Epidermal Cells in Hypertrophic Scarring Pathology. Wound Repair Regen 2008. [DOI: 10.1111/j.1067-1927.2005.130216bb.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Mayrand D, Cordier B, Blanchette S, Lopez‐Vallé CA, Roy M, Genest H, Moulin V. New role of Human myofibroblasts on neovascularisation during wound healing. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.901.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | | | - Michel Roy
- Hôpital de l’Enfant‐Jésus ‐ CHAUQQuebecQcCanada
| | | | - Véronique Moulin
- SurgeryLaval UniversityQuebecQcCanada
- LOEX‐CHA‐Laval UniversityQuebecQcCanada
| |
Collapse
|
41
|
Corriveau M, Boufaied I, Lessard J, Chabaud S, Grodzicky T, Senécal J, Moulin V. New hypothesis concerning pathogenesis of systemic sclerosis using a tissue engineering method. FASEB J 2008. [DOI: 10.1096/fasebj.22.1_supplement.464.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
42
|
Seaborn T, St-Amand J, Cloutier M, Tremblay MG, Maltais F, Dinel S, Moulin V, Khan PA, Piedboeuf B. Identification of cellular processes that are rapidly modulated in response to tracheal occlusion within mice lungs. Pediatr Res 2008; 63:124-30. [PMID: 18091360 DOI: 10.1203/pdr.0b013e31815eba47] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Lung development progresses through a process reliant on mechanical cell stretch. However, this process is not well defined at the molecular level. Our goal was to globally analyze the transcriptome of fetal mouse lungs following short periods of tracheal occlusion (TO) to identify cellular processes that are rapidly modulated in response to intraluminal stretch increase. Serial analysis of gene expression (SAGE) was used to examine the global transcriptomic response of mouse prealveolar stage lungs to in vivo TO at 1 and 3 h. SAGE results were extended by histo- and immunochemical examination. Based on the 97 TO-modulated transcripts identified, our results further point out that continuous stretch in developing lungs leads directly to rapid and highly specific phenotypic modifications in a significant proportion of pulmonary cells. We conclude that intraluminal stretch increase during prealveolar stage of lung development induces a critical transition of pulmonary cells phenotype in which there is an increase in alpha-smooth muscle actin (alpha-SMA)-containing cells along with a relative decrease in lipid-containing cells.
Collapse
Affiliation(s)
- Tommy Seaborn
- Pediatric Research Unit, Laval University, Ste-Foy, Québec, G1V 4G2, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Eleveld-Trancikova D, Janssen RAJ, Hendriks IAM, Looman MWG, Moulin V, Jansen BJH, Jansen JH, Figdor CG, Adema GJ. The DC-derived protein DC-STAMP influences differentiation of myeloid cells. Leukemia 2007; 22:455-9. [PMID: 17713547 DOI: 10.1038/sj.leu.2404910] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Aparicio T, Costes L, Moulin V, Locher C, Bidault A, Lecomte T, Mitry E, Taieb J, Landi B, Malka D. Efficacy of recent chemotherapy regimen in advanced small bowel carcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15112] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15112 Background: Small bowel carcinoma (SBC) is a rare tumour. Very few data concerning the chemotherapy efficacy are published. The overall survivals previously reported were 8 to 14 months. The aim of the study was to evaluate the efficacy of recent chemotherapy regimen in advanced SBC. Methods: All the consecutive patients treated recently by first line chemotherapy for advanced SBC were included retrospectively in a multicentric study. Clinical and radiological evaluations were performed every 2 or 3 months according to WHO criteria. Chemotherapy was stopped in case of progression, severe toxicity or patient willing. Results: Fifty seven patients (33 men, 24 women), median age 56 years [32–83] treated from 1994 to 2006 in 10 institutions were included. Primary tumours were: duodenum n=35 (61%), jejunum n=14 (25%) and ileum n=8 (14%). Three patients had Crohn disease and one HNPCC syndrome. The tumour were locally advanced in 6 patients (10%), or with metastasis in 51 (90%), synchronous n=35 or metachronous n=16. The mains metastasis sites were peritoneal carcinomatosis in 29, liver in 19 and nodes in 13 patients. Sixteen patients have had an initial R0 surgery and 8 had received, before inclusion, adjuvant chemotherapy. The regimens used in first line were: FOLFOX n=21 (37%), LV5FU2-cisplatine n=13 (23%), LV5FU2 n=12 (21%), FOLFIRI n=10 (17%). Twenty five (44%) patients have had grade 3 or 4 toxicity. A toxic death occurred after a cure of FOLFOX. Chemotherapy was stopped in relation to toxicity in 7 (12%) patients. A dose reduction was done in 15 (26%) patients for a total of 16% of the cures. Tumor was measurable in 42 (73%) pts. A partial response was observed in 13 patients (31%), stabilisation in 14 (33%) and progression in 15 (36%). Thirty six (63%) pts had a second line chemotherapy. Time to treatment failure was 6 [1–21] months in all patients and 7 [2–19], 7 [2–20], 5 [1–21] and 4 [1–10] months according to treatment by FOLFOX, LV5FU2, FOLFIRI or LV5FU2-cisplatine respectively. Overall survival was 11 months [1–36]. Overall survival according to the primary localization were: duodenum: 9 [1–34], jejunum: 18 [3–32], ileum: 15 [4- 36]. Conclusions: Advanced SBC have a bad prognosis. The chemotherapy regimen used in colon cancer did not reach the same efficacy in SBC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- T. Aparicio
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - L. Costes
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - V. Moulin
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - C. Locher
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - A. Bidault
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - T. Lecomte
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - E. Mitry
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - J. Taieb
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - B. Landi
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| | - D. Malka
- Hôpital Bichat, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint Antoine, Paris, France; Hôpital de Meaux, Meaux, France; Hôpital Kremlin Bicêtre, Kremlin Bicêtre, France; Hôpital Trousseau, Tours, France; Hôpital Ambroise Paré, Boulogne, France; Hôpital de la Pitié- Salpétrière, Paris, France; Hôpital Georges Pompidou, Paris, France
| |
Collapse
|
45
|
Mayrand D, Lopez‐Vallé CA, Roy M, Moulin V. Myofibroblasts from skin wound and hypertrophic scar present different apoptotic response to body fluids. FASEB J 2007. [DOI: 10.1096/fasebj.21.6.a759-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Carlos A Lopez‐Vallé
- SurgeryComplexe Hospitalier de la Sagamie305 ave St‐Vallier, C.P. 5006ChicoutimiG7H 5H6Canada
| | - Michel Roy
- SurgeryCHAUQ1050 ch. Ste‐FoyQuebecG1S 4L8Canada
| | | |
Collapse
|
46
|
Ansoborlo E, Bion L, Doizi D, Moulin C, Lourenco V, Madic C, Cote G, Van der Lee J, Moulin V. Current and future radionuclide speciation studies in biological media. Radiat Prot Dosimetry 2007; 127:97-102. [PMID: 17578878 DOI: 10.1093/rpd/ncm258] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Radionuclides may be released into the environment accidentally or incidentally, which could raise health risks when ingested or inhaled by humans. In order to study the behaviour of radionuclides in the human organism (metabolism, retention, excretion), knowledge of radionuclide speciation is indispensable: speciation governs the transfer, bioavailability and toxicity of elements and is also of considerable interest for decorporation. In this context, the Commissariat à l'Energie Atomique has created a working group on speciation to share data both on thermodynamic constants and on speciation analysis methods of interest to chemists, environmentalists and biologists. The initial focus was on the 31 radionuclides described in different International Commission on Radiological Protection models (HRTM, HAT) and the National Council on Radiation Protection model (wound). Particular attention was devoted to selecting the inorganic and organic ligands, most representative of biological media. The base applied to speciation in solution and at interfaces and solubility (BASSIST) thermodynamic database was developed for this purpose. The aim of this paper is to present the state of the art on radionuclide speciation tools within biological media and to emphasise some missing data in order to orient future research.
Collapse
Affiliation(s)
- E Ansoborlo
- CEA/DEN/DRCP/CETAMA, VRH-Marcoule, BP 17171, 30207 Bagnols-sur-Cèze, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ansoborlo E, Santucci C, Grouiller JP, Boucher L, Flüry-Herard A, Menetrier F, Comte A, Cook E, Moulin V. Development of a database: DACTARI for a radiotoxic element ranking methodology. Radiat Prot Dosimetry 2007; 127:526-30. [PMID: 17578873 DOI: 10.1093/rpd/ncm305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Dosimetric impact studies aim at evaluating potential radiological effects of chronic or acute releases from nuclear facilities. A methodology for ranking radionuclides (RN) in terms of their health-related impact on the human population was first developed at CEA with specific criteria for each RN that could be applied to a variety of situations. It is based, in particular, on applying physico-chemical criteria to the complete RN inventory (present in the release or in the source term) and on applying norms related to radiation protection and chemical toxicology. The initial step consisted in identifying and collecting data necessary to apply the methodology, with reference to a previous database of long-lived radionuclides (LLRN, with half-lives ranging from 30 to 10(14) y) containing 95 radionuclides. The initial results have allowed us to identify missing data and revealed the need to complete the study for both toxic and radiotoxic aspects. This led us to the next step, developing a specific database, DAtabase for Chemical Toxicity and Radiotoxicity Assessment of RadIonuclides (DACTARI), to collect data on chemical toxicity and radiotoxicity, including acute or chronic toxicity, the chemical form of the compounds, the contamination route (ingestion, inhalation), lethal doses, target organs, intestinal and maternal-foetal transfer, drinking water guidelines and the mutagenic and carcinogenic properties.
Collapse
Affiliation(s)
- E Ansoborlo
- CEA/DEN/DRCP/CETAMA, VRH-Marcoule, BP 17171, 30207 Bagnol-sur-Cèze, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Auger FA, Berthod F, Moulin V, Pouliot R, Germain L. Tissue-engineered skin substitutes: from in vitro constructs to in vivo applications. Biotechnol Appl Biochem 2004; 39:263-75. [PMID: 15154837 DOI: 10.1042/ba20030229] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The field of skin tissue engineering is a paradigm for the various efforts towards the reconstruction of other tissues and organ substitutes. As skin replacement, this biotechnological approach has evolved from simple cultured autologous epidermal sheets to more complex bilayered cutaneous substitutes. The various types of such substitutes are herein presented with their intended use. However, two integrative characteristics are analysed more specifically because of their critical role: neovascularization and re-innervation. Furthermore, the in vitro use of these various skin substitutes has shed light on various physiological and pathological phenomena. Thus, not only the in vivo application of these skin substitutes as grafts, but also their in vitro value as skin models, are presented.
Collapse
Affiliation(s)
- François A Auger
- Laboratoire d'Organogénèse Expérimentale/LOEX, Saint-Sacrement Hospital, and Department of Surgery, Faculty of Medicine, Laval University, Québec, QC, Canada G1S 4L8.
| | | | | | | | | |
Collapse
|
49
|
Moulin V, Larochelle S, Langlois C, Thibault I, Lopez-Vallé CA, Roy M. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 2004; 198:350-8. [PMID: 14755540 DOI: 10.1002/jcp.10415] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
During wound healing, myofibroblasts play a central role in matrix formation and wound contraction. At the end of healing, there is evidence that myofibroblasts disappear via apoptotic pathways. Hypertrophic scars are a fibroproliferative disorder that leads to considerable morbidity. It has been postulated that a defect in myofibroblast apoptosis could be responsible for the pathological scar formation, but no evidence exists. We have isolated and cultured human normal wound (Wmyo) and hypertrophic scar (Hmyo) myofibroblasts and compared their basal apoptotic rates and their sensitivity to serum starvation and Fas antibody-induced apoptosis to that obtained for dermal fibroblasts (Fb). A higher rate of apoptosis as evidenced by morphological criteria and a propidium iodide assay was observed for Wmyo in comparison to Fb and Hmyo. These results came along with a low level of the anti-apoptotic proteins Bcl-2 and Bclx(L) in Wmyo, whereas there was an increase in the level of the pro-apoptotic molecule Bax when compared to the results obtained for Fb and Hmyo. Hmyo showed a higher level of Bcl-2 compared to Fb but no difference in the Bax or Bclx(L) level. After serum starvation, Wmyo revealed an increased apoptotic rate, whereas Hmyo and Fb did not show any difference. Anti-Fas treatment did not modify the levels of apoptosis but strongly increased the cell growth of Hmyo as compared to Wmyo. This is the first study presenting a broad vision of the apoptotic sensitivity of normal and pathological myofibroblasts. These results confirmed the hypothesis of defects in apoptosis and growth during pathological scar formation impeding myofibroblast disappearance at the end of healing.
Collapse
Affiliation(s)
- Véronique Moulin
- Laboratoires des grands brûlés/LOEX, Hôpital du Saint-Sacrement du Centre Hospitalier Affilié Université de Québec, Québec, Canada.
| | | | | | | | | | | |
Collapse
|
50
|
Paquette JS, Moulin V, Tremblay P, Bernier V, Boutet M, Laviolette M, Auger FA, Boulet LP, Goulet F. Tissue-engineered human asthmatic bronchial equivalents. Eur Cell Mater 2004; 7:1-11; discussion 1-11. [PMID: 15015133 DOI: 10.22203/ecm.v007a01] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The isolation of human bronchial epithelial (HBEC) and fibroblastic cells (HBFC) from biopsies of asthmatic and non-asthmatic volunteers provided unique cellular materials to be used for the production of bioengineered bronchial equivalents (BE) in vitro. The HBEC are grown on a mesenchymal layer seeded with HBFC and the BE can be maintained for at least 15 days in culture. Under the BE culture conditions established previously, HBEC undergo differentiation into ciliated and goblet cells, within a pseudostratified organization comparable to human bronchi. We published previously the results from histologic and functional analyses of such BE produced exclusively using non-asthmatic HBEC and HBFC. We report here the comparative analyses of BE produced with non-asthmatic and asthmatic living HBEC and HBFC (naBE and aBE, respectively). Our data indicated that all asthmatic HBEC populations grown on a mesenchymal layer, containing non-asthmatic HBFC, slowly reached a confluent state but then detached from the matrix upon culture time. These BE appear to be very good models to study the mechanisms involved in asthma in vitro.
Collapse
|